Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARVIND CHAUDHRY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1750336236
CMS profile
34432
Location
SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$11,319.90

290 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,827.74 265
Honoraria $2,700.00 1
Long term medical supply or device loan $1,163.66 12
Travel and Lodging $1,135.16 6
Education $493.34 6

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $4,470.05 26
Novartis Pharmaceuticals Corporation $1,510.35 35
Janssen Biotech, Inc. $481.75 16
Merck Sharp & Dohme LLC $475.74 17
PFIZER INC. $345.13 18
AstraZeneca Pharmaceuticals LP $282.33 13
E.R. Squibb & Sons, L.L.C. $228.03 12
TerSera Therapeutics LLC $226.93 7
ABBVIE INC. $209.38 10
SEAGEN INC. $199.90 2
Incyte Corporation $197.12 10
BeOne Medicines USA, Inc. $168.78 7
GlaxoSmithKline, LLC. $166.61 12
Celgene Corporation $153.68 12
Lilly USA, LLC $152.06 6
Iovance Biotherapeutics, Inc. $130.99 4
EMD Serono, Inc. $119.59 5
GENZYME CORPORATION $104.23 4
Astellas Pharma US Inc $103.40 4
Takeda Pharmaceuticals U.S.A., Inc. $102.34 3
Regeneron Healthcare Solutions, Inc. $97.41 3
Aveo Pharmaceuticals, Inc. $88.66 4
ARRAY BIOPHARMA INC $70.62 4
Stemline Therapeutics Inc. $70.07 3
Azurity Pharmaceuticals, Inc. $66.70 3
Sumitomo Pharma America, Inc. $64.27 3
Daiichi Sankyo Inc. $64.19 3
Bayer Healthcare Pharmaceuticals Inc. $60.44 3
Eisai Inc. $53.63 3
Genentech, Inc. $53.45 1
Blueprint Medicines Corporation $50.68 2
Gilead Sciences, Inc. $49.65 2
Syndax Pharmaceuticals, Inc. $48.88 2
RECORDATI_RARE_DISEASES_INC. $48.46 2
Genentech USA, Inc. $38.52 2
Pharmacosmos Therapeutics Inc. $36.64 2
Immunocore Limited $31.95 1
ACCORD HEALTHCARE, INC. $31.81 2
Caris MPI, Inc. $31.34 2
Legend Biotech USA Inc. $30.95 2
Alnylam Pharmaceuticals Inc. $29.39 1
SOBI, INC $28.34 1
Coherus Oncology, Inc. $28.14 1
Rigel Pharmaceuticals, Inc. $28.08 1
Genmab U.S., Inc. $27.17 1
BeiGene USA, Inc. $26.66 1
Agios Pharmaceuticals, Inc. $25.22 1
Acrotech Biopharma Inc. $24.71 1
JAZZ PHARMACEUTICALS INC. $24.71 1
Dendreon Pharmaceuticals LLC $24.21 1
PUMA BIOTECHNOLOGY, INC. $19.69 1
Spectrum Pharmaceuticals Inc. $18.79 1
SpringWorks Therapeutics, Inc. $18.38 1
Geron Corporation $17.44 1
Amneal Pharmaceuticals LLC $16.01 1
pharmaand GmbH $16.00 1
Helsinn Therapeutics (U.S.), Inc. $15.28 1
SERVIER PHARMACEUTICALS LLC $14.97 1

Page 2 of 6; records 51–100 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARVIND CHAUDHRY

NPI 1750336236 · CMS profile ID 34432

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750336236?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARVIND CHAUDHRY, NPI 1750336236, CMS profile ID 34432. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750336236?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ARVIND CHAUDHRY, NPI 1750336236, CMS profile ID 34432. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750336236?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ARVIND CHAUDHRY, NPI 1750336236, CMS profile ID 34432, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1750336236?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

290 matching records · $11,319.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 290 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 290.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $23.9810/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225983094 CMS
Sumitomo Pharma America, Inc. $20.3310/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176621713 CMS
Novartis Pharmaceuticals Corporation $28.4910/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200123436 CMS
Helsinn Therapeutics (U.S.), Inc. $15.2810/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186334139 CMS
Merck Sharp & Dohme LLC $27.0010/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238381448 CMS
Merck Sharp & Dohme LLC $28.9510/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238282291 CMS
Novartis Pharmaceuticals Corporation $14.6810/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200123514 CMS
Lilly USA, LLC $26.5010/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186515483 CMS
E.R. Squibb & Sons, L.L.C. $24.6710/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184883277 CMS
TerSera Therapeutics LLC $26.2010/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244053995 CMS
JAZZ PHARMACEUTICALS INC. $24.7110/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234329953 CMS
Novartis Pharmaceuticals Corporation $16.4810/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200123518 CMS
Novartis Pharmaceuticals Corporation $18.8209/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200123512 CMS
Astellas Pharma US Inc $22.3009/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238670513 CMS
Daiichi Sankyo Inc. $23.3709/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197092233 CMS
EMD Serono, Inc. $22.1309/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236882223 CMS
Eisai Inc. $17.3509/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244463801 CMS
Rigel Pharmaceuticals, Inc. $28.0809/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247377780 CMS
SEAGEN INC. $99.9509/22/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1229900055 CMS
Novartis Pharmaceuticals Corporation $99.7009/19/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200123452 CMS
PFIZER INC. $29.2209/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230362781 CMS
Exelixis Inc. $2,700.0009/18/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1218791595 CMS
PFIZER INC. $20.4609/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230447219 CMS
Novartis Pharmaceuticals Corporation $17.4509/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200123516 CMS
Merck Sharp & Dohme LLC $25.7109/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238329643 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.8909/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225492612 CMS
Celgene Corporation $13.4009/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184883267 CMS
Exelixis Inc. $124.5009/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1218791575 CMS
Exelixis Inc. $293.1809/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1218791579 CMS
Exelixis Inc. $29.2709/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218791581 CMS
Exelixis Inc. $58.5409/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218791585 CMS
Exelixis Inc. $596.9609/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1218791587 CMS
Exelixis Inc. $90.6009/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218791589 CMS
Exelixis Inc. $70.0009/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1218791591 CMS
Exelixis Inc. $68.1809/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218791577 CMS
Exelixis Inc. $30.5209/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1218791583 CMS
Exelixis Inc. $20.0009/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1218791593 CMS
Iovance Biotherapeutics, Inc. $27.8109/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251397117 CMS
Immunocore Limited $31.9509/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235826557 CMS
Iovance Biotherapeutics, Inc. $44.0709/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251397121 CMS
SOBI, INC $28.3409/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240272103 CMS
Takeda Pharmaceuticals U.S.A., Inc. $33.1209/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223930786 CMS
AstraZeneca Pharmaceuticals LP $22.3308/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206190008 CMS
ABBVIE INC. $24.1208/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201639465 CMS
PFIZER INC. $25.3508/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229557858 CMS
AstraZeneca Pharmaceuticals LP $14.3708/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207282307 CMS
AstraZeneca Pharmaceuticals LP $16.0908/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206513564 CMS
GlaxoSmithKline, LLC. $16.0108/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191224018 CMS
Merck Sharp & Dohme LLC $31.6108/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238238140 CMS
Novartis Pharmaceuticals Corporation $99.7008/21/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200123428 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $24,513.27 302
PY2020 $7,009.94 211
PY2021 $5,124.96 241
PY2022 $10,268.52 223
PY2023 $7,742.63 223
PY2024 $5,099.97 228
PY2025 $11,319.90 290

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $120.37 3
PY2025 Principal investigator $983,880.56 173
PY2024 Principal investigator $999,041.50 152
PY2023 Principal investigator $2,006,085.88 155
PY2022 Principal investigator $1,788,082.83 163
PY2021 Principal investigator $2,822,985.04 252
PY2020 Recipient $10,000.00 1
PY2020 Principal investigator $2,128,155.63 311
PY2019 Recipient $9,301.70 4
PY2019 Principal investigator $657,825.25 132

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

176 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $2,529.76 12/31/2025 Non-covered Recipient Entity
Medical Oncology Associates Summit Cancer Centers
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 1232925793
Principal investigator 1 Merck Sharp & Dohme LLC $4,253.54 12/31/2025 Non-covered Recipient Entity
Medical Oncology Associates Summit Cancer Centers
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re No dispute reported 06/30/2026 1232926707
Principal investigator 1 BeOne Medicines USA, Inc. $25,076.00 12/30/2025 Non-covered Recipient Entity
Medical Oncology Associates, PS
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329689
Principal investigator 1 Janssen Research & Development, LLC $9,393.00 12/22/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175399559
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,090.00 12/19/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 No dispute reported 06/30/2026 1185537567
Principal investigator 1 ABBVIE INC. $1,718.55 12/04/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202528410
Principal investigator 1 Partner Therapeutics, Inc. $1,712.40 11/26/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS DBA SUMMIT CANCER CENTERS
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) No dispute reported 06/30/2026 1215516804
Principal investigator 1 PFIZER INC. $1,537.28 11/24/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228813733
Principal investigator 1 PFIZER INC. $6,145.00 11/17/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228813751
Principal investigator 1 Janssen Research & Development, LLC $17,860.37 11/14/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175399575
Principal investigator 1 ABBVIE INC. $19,227.50 11/05/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202523143
Principal investigator 1 Daiichi Sankyo Inc. $51.75 11/03/2025 Non-covered Recipient Entity
Medical Oncology Associates P S Spokane
DS1062-328 No dispute reported 06/30/2026 1223372102
Principal investigator 1 Daiichi Sankyo Inc. $94.00 11/03/2025 Non-covered Recipient Entity
Medical Oncology Associates P S Spokane
DS1062-328 No dispute reported 06/30/2026 1223372104
Principal investigator 1 Daiichi Sankyo Inc. $376.00 11/03/2025 Non-covered Recipient Entity
Medical Oncology Associates P S Spokane
DS1062-328 No dispute reported 06/30/2026 1223372106
Principal investigator 1 Janssen Research & Development, LLC $9,393.00 11/03/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175399548
Principal investigator 1 Partner Therapeutics, Inc. $10,661.10 10/31/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS DBA SUMMIT CANCER CENTERS
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) No dispute reported 06/30/2026 1215516593
Principal investigator 1 Partner Therapeutics, Inc. $2,825.00 10/31/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS DBA SUMMIT CANCER CENTERS
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) No dispute reported 06/30/2026 1215516810
Principal investigator 1 ABBVIE INC. $2,000.00 10/16/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202517379
Principal investigator 1 ABBVIE INC. $4,094.87 10/16/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202517381
Principal investigator 1 ABBVIE INC. $1,500.00 10/16/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202517383
Principal investigator 1 ABBVIE INC. $750.00 10/16/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202517385
Principal investigator 1 ABBVIE INC. $1,500.00 10/16/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202517397
Principal investigator 1 ABBVIE INC. $2,250.00 10/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202516439
Principal investigator 1 Exelixis Inc. $2,079.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381580
Principal investigator 1 Exelixis Inc. $1,049.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381582
Principal investigator 1 Exelixis Inc. $396.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381584
Principal investigator 1 Exelixis Inc. $1,980.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381586
Principal investigator 1 Exelixis Inc. $594.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381588
Principal investigator 1 Exelixis Inc. $3,465.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381590
Principal investigator 1 Exelixis Inc. $495.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381592
Principal investigator 1 Exelixis Inc. $2,640.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381594
Principal investigator 1 Exelixis Inc. $132.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381596
Principal investigator 1 Exelixis Inc. $6,501.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381598
Principal investigator 1 Exelixis Inc. $792.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381600
Principal investigator 1 Exelixis Inc. $2,059.00 10/06/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381602
Principal investigator 1 Organon Llc $20,508.00 09/24/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
1026-003 No dispute reported 06/30/2026 1173042146
Principal investigator 1 Organon Llc $2,600.00 09/24/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
1026-003 No dispute reported 06/30/2026 1173042412
Principal investigator 1 Organon Llc $30,807.00 09/19/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
1026-003 No dispute reported 06/30/2026 1173042410
Principal investigator 1 Exelixis Inc. $4,011.00 09/08/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222381606
Principal investigator 1 Exelixis Inc. $170.00 09/08/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222381608
Principal investigator 1 Exelixis Inc. $592.00 09/08/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222381610
Principal investigator 1 Organon Llc $6,010.80 09/08/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
2140-006 No dispute reported 06/30/2026 1173042528
Principal investigator 1 Janssen Research & Development, LLC $3,131.00 09/01/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175399593
Principal investigator 1 Amgen Inc. $3,550.00 08/22/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression No dispute reported 06/30/2026 1246644179
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,374.67 08/13/2025 Non-covered Recipient Entity
Medical Oncology Associates, Ps
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1235995917
Principal investigator 1 Janssen Research & Development, LLC $17,168.00 08/11/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175399568
Principal investigator 1 AstraZeneca UK Limited $27,553.00 07/31/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
phase two open label single arm trial of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma after first line acalabrutinib progression No dispute reported 06/30/2026 1185537565
Principal investigator 1 Exelixis Inc. $6,769.60 07/23/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381566
Principal investigator 1 Janssen Research & Development, LLC $13,750.00 07/22/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175399598
Principal investigator 1 Amgen Inc. $83,008.55 07/18/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer No dispute reported 06/30/2026 1246644188
Principal investigator 1 Exelixis Inc. $1,793.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381548
Principal investigator 1 Exelixis Inc. $9,093.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381550
Principal investigator 1 Exelixis Inc. $1,365.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381552
Principal investigator 1 Exelixis Inc. $479.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381554
Principal investigator 1 Exelixis Inc. $550.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381556
Principal investigator 1 Exelixis Inc. $7,218.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381558
Principal investigator 1 Exelixis Inc. $1,917.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381560
Principal investigator 1 Exelixis Inc. $36,654.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381562
Principal investigator 1 Exelixis Inc. $2,000.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381564
Principal investigator 1 Exelixis Inc. $44.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381568
Principal investigator 1 Exelixis Inc. $655.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381570
Principal investigator 1 Exelixis Inc. $1,500.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381572
Principal investigator 1 Exelixis Inc. $1,519.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381574
Principal investigator 1 Exelixis Inc. $4,111.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381576
Principal investigator 1 Exelixis Inc. $2,500.00 07/09/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381578
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 06/26/2025 Non-covered Recipient Entity
Medical Oncology Associates, PS
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190330125
Principal investigator 1 Gilead Sciences, Inc. $29,249.00 06/13/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES P S
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physican's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04) No dispute reported 06/30/2026 1229213455
Principal investigator 1 PFIZER INC. $1,537.28 06/02/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228844031
Recipient ABBVIE INC. $25.00 05/30/2025 Covered Recipient Physician A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202397637
Recipient ABBVIE INC. $47.37 05/30/2025 Covered Recipient Physician A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202397640
Recipient ABBVIE INC. $48.00 05/30/2025 Covered Recipient Physician A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202397644
Principal investigator 1 PFIZER INC. $5,020.00 05/19/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228844192
Principal investigator 1 ABBVIE INC. $688.77 05/15/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202485235
Principal investigator 1 Merck Sharp & Dohme LLC $71,000.00 05/11/2025 Non-covered Recipient Entity
Medical Oncology Associates
A Phase I, Open-label, Multicenter Study of ZL 1218 as a Single Agent and as Combination Therapy with Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Advanced Solid Tumor Malignancies No dispute reported 06/30/2026 1232935505
Principal investigator 1 Janssen Research & Development, LLC $9,834.00 05/08/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175399588
Principal investigator 1 Janssen Research & Development, LLC $31,910.00 04/08/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175399564
Principal investigator 1 Janssen Research & Development, LLC $47,985.00 04/08/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175399582
Principal investigator 1 Janssen Research & Development, LLC $13,200.00 03/28/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175399554
Principal investigator 1 Acerta Pharma LLC $10,726.62 03/27/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation No dispute reported 06/30/2026 1185537563
Principal investigator 1 Merck Sharp & Dohme LLC $8,453.76 03/20/2025 Non-covered Recipient Entity
Summit Cancer Centers
A Phase 1b,2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an oral TGF R Serine,Threonine Kinase Inhibitor, Administered in Combination with Pembrolizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232932117
Principal investigator 1 Acerta Pharma LLC $8,134.01 03/18/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
a randomized,multicenter,open label,3 arm phase 3 study of obinutuzumab in combination with chlorambucil,ACP 196 in combination with obinutuzumaband ACP 196 monotherapy in subjects with previously untreated chronic lymphocytic leukemia No dispute reported 06/30/2026 1185537561
Principal investigator 1 PFIZER INC. $7,240.00 03/10/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228846157
Principal investigator 1 AstraZeneca UK Limited $37,211.62 02/28/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1185537559
Principal investigator 1 Exelixis Inc. $360.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381408
Principal investigator 1 Exelixis Inc. $170.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381410
Principal investigator 1 Exelixis Inc. $214.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381412
Principal investigator 1 Exelixis Inc. $148.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381418
Principal investigator 1 Exelixis Inc. $61.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381420
Principal investigator 1 Exelixis Inc. $176.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381422
Principal investigator 1 Exelixis Inc. $124.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381424
Principal investigator 1 Exelixis Inc. $122.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381428
Principal investigator 1 Exelixis Inc. $4,111.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381430
Principal investigator 1 Exelixis Inc. $61.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381432
Principal investigator 1 Exelixis Inc. $73.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381434
Principal investigator 1 Exelixis Inc. $130.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381438
Principal investigator 1 Exelixis Inc. $81.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381440
Principal investigator 1 Exelixis Inc. $97.01 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381442
Principal investigator 1 Exelixis Inc. $122.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381444
Principal investigator 1 Exelixis Inc. $64.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381448
Principal investigator 1 Exelixis Inc. $410.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381450
Principal investigator 1 Exelixis Inc. $54.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381452
Principal investigator 1 Exelixis Inc. $172.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381454
Principal investigator 1 Exelixis Inc. $116.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381456
Principal investigator 1 Exelixis Inc. $162.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381458
Principal investigator 1 Exelixis Inc. $136.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381460
Principal investigator 1 Exelixis Inc. $63.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381462
Principal investigator 1 Exelixis Inc. $74.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381464
Principal investigator 1 Exelixis Inc. $5,817.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381466
Principal investigator 1 Exelixis Inc. $205.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381468
Principal investigator 1 Exelixis Inc. $88.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381470
Principal investigator 1 Exelixis Inc. $65.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381472
Principal investigator 1 Exelixis Inc. $2,406.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381474
Principal investigator 1 Exelixis Inc. $406.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381476
Principal investigator 1 Exelixis Inc. $221.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381478
Principal investigator 1 Exelixis Inc. $122.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381480
Principal investigator 1 Exelixis Inc. $406.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381482
Principal investigator 1 Exelixis Inc. $62.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381484
Principal investigator 1 Exelixis Inc. $128.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381486
Principal investigator 1 Exelixis Inc. $122.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381488
Principal investigator 1 Exelixis Inc. $88.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381490
Principal investigator 1 Exelixis Inc. $136.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381492
Principal investigator 1 Exelixis Inc. $172.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381494
Principal investigator 1 Exelixis Inc. $221.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381496
Principal investigator 1 Exelixis Inc. $371.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381498
Principal investigator 1 Exelixis Inc. $254.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381500
Principal investigator 1 Exelixis Inc. $190.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381502
Principal investigator 1 Exelixis Inc. $3,031.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381504
Principal investigator 1 Exelixis Inc. $95.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381506
Principal investigator 1 Exelixis Inc. $86.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381508
Principal investigator 1 Exelixis Inc. $2,000.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381510
Principal investigator 1 Exelixis Inc. $256.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381512
Principal investigator 1 Exelixis Inc. $68.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381514
Principal investigator 1 Exelixis Inc. $1,793.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381518
Principal investigator 1 Exelixis Inc. $108.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381520
Principal investigator 1 Exelixis Inc. $122.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381522
Principal investigator 1 Exelixis Inc. $80.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381524
Principal investigator 1 Exelixis Inc. $80.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381526
Principal investigator 1 Exelixis Inc. $63.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381528
Principal investigator 1 Exelixis Inc. $131.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381530
Principal investigator 1 Exelixis Inc. $4,111.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381532
Principal investigator 1 Exelixis Inc. $61.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381536
Principal investigator 1 Exelixis Inc. $146.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381538
Principal investigator 1 Exelixis Inc. $176.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381540
Principal investigator 1 Exelixis Inc. $61.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381542
Principal investigator 1 Exelixis Inc. $2,730.00 02/21/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381546
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,568.00 02/20/2025 Non-covered Recipient Entity
Summit Cancer Centers North Spokane
Brightline-4 No dispute reported 06/30/2026 1220817402
Principal investigator 1 Acerta Pharma LLC $27,927.69 02/18/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185537557
Principal investigator 1 Exelixis Inc. $86.00 02/12/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381414
Principal investigator 1 Exelixis Inc. $820.00 02/12/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381416
Principal investigator 1 Exelixis Inc. $54.00 02/12/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381426
Principal investigator 1 Exelixis Inc. $81.00 02/12/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381436
Principal investigator 1 Exelixis Inc. $240.00 02/12/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381446
Principal investigator 1 Exelixis Inc. $32.00 02/12/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381516
Principal investigator 1 Exelixis Inc. $186.00 02/12/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381534
Principal investigator 1 Exelixis Inc. $219.00 02/12/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. No dispute reported 06/30/2026 1222381544
Principal investigator 1 Amgen Inc. $1,227.00 01/29/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer No dispute reported 06/30/2026 1246644191
Principal investigator 1 Exelixis Inc. $33,530.00 01/24/2025 Non-covered Recipient Entity
Medical Oncology Associates PS
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222381604
Principal investigator 1 Eli Lilly and Company $29,758.06 01/22/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES PS
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) No dispute reported 06/30/2026 1187886518
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,500.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910481
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,500.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910483
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,600.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910485
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,060.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910487
Principal investigator 1 Aveo Pharmaceuticals, Inc. $750.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910489
Principal investigator 1 Aveo Pharmaceuticals, Inc. $10,000.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910491
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,100.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910493
Principal investigator 1 Aveo Pharmaceuticals, Inc. $755.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910495
Principal investigator 1 Aveo Pharmaceuticals, Inc. $998.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910497
Principal investigator 1 Aveo Pharmaceuticals, Inc. $700.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910499
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,700.00 01/09/2025 Non-covered Recipient Entity
MEDICAL ONCOLOGY ASSOCIATES, P.S.
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199910501
Principal investigator 1 BeiGene, Ltd. $1,500.00 01/06/2025 Non-covered Recipient Entity
Medical Oncology Associates, PS
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320010
Principal investigator 1 BeiGene, Ltd. $2,275.00 01/06/2025 Non-covered Recipient Entity
Medical Oncology Associates, PS
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324174
Principal investigator 1 BeiGene, Ltd. $750.00 01/06/2025 Non-covered Recipient Entity
Medical Oncology Associates, PS
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324620
Principal investigator 1 BeiGene, Ltd. $2,000.00 01/06/2025 Non-covered Recipient Entity
Medical Oncology Associates, PS
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324632
Principal investigator 1 BeiGene, Ltd. $680.00 01/06/2025 Non-covered Recipient Entity
Medical Oncology Associates, PS
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324654
Principal investigator 1 BeiGene, Ltd. $2,500.00 01/06/2025 Non-covered Recipient Entity
Medical Oncology Associates, PS
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324668
Principal investigator 1 BeiGene, Ltd. $5,592.00 01/06/2025 Non-covered Recipient Entity
Medical Oncology Associates, PS
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324680